Harnessing Neoantigen Specific CD4 T Cells for Cancer Immunotherapy

Overview

Journal J Leukoc Biol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 2020 Mar 15

PMID 32170883

Citations 28

Authors

Spencer E Brightman

Martin S Naradikian

Aaron M Miller

Stephen P Schoenberger

Affiliations

Soon will be listed here.

Abstract

The goal of precision immunotherapy is to direct a patient's T cell response against the immunogenic mutations expressed on their tumors. Most immunotherapy approaches to-date have focused on MHC class I-restricted peptide epitopes by which cytotoxic CD8 T lymphocytes (CTL) can directly recognize tumor cells. This strategy largely overlooks the critical role of MHC class II-restricted CD4 T cells as both positive regulators of CTL and other effector cell types, and as direct effectors of antitumor immunity. In this review, we will discuss the role of neoantigen specific CD4 T cells in cancer immunotherapy and how existing treatment modalities may be leveraged to engage this important T cell subset.

Citing Articles

Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer.

Morisaki T, Kubo M, Morisaki S, Umebayashi M, Tanaka H, Koya N Cancers (Basel). 2025; 16(24.

PMID: 39766103 PMC: 11674441. DOI: 10.3390/cancers16244204.

Adenoviral-vectored neoantigen vaccine augments hyperexpanded CD8 T cell control of tumor challenge in mice.

Dagotto G, Colarusso A, Patio R, Li D, Anioke T, Giffin V J Immunother Cancer. 2024; 12(12).

PMID: 39694702 PMC: 11660326. DOI: 10.1136/jitc-2024-009644.

Comparing neoantigen cancer vaccines and immune checkpoint therapy unveils an effective vaccine and anti-TREM2 macrophage-targeting dual therapy.

Keshari S, Shavkunov A, Miao Q, Saha A, Minowa T, Molgora M Cell Rep. 2024; 43(11):114875.

PMID: 39446585 PMC: 11785356. DOI: 10.1016/j.celrep.2024.114875.

Advancing Cholangiocarcinoma Care: Insights and Innovations in T Cell Therapy.

Dadgar N, Arunachalam A, Hong H, Phoon Y, Arpi-Palacios J, Uysal M Cancers (Basel). 2024; 16(18).

PMID: 39335203 PMC: 11429565. DOI: 10.3390/cancers16183232.

Necroptosis stimulates interferon-mediated protective anti-tumor immunity.

Rucker A, Park C, Li Q, Moseman E, Chan F Cell Death Dis. 2024; 15(6):403.

PMID: 38858387 PMC: 11164861. DOI: 10.1038/s41419-024-06801-8.

References

Alspach E, Lussier D, Miceli A, Kizhvatov I, DuPage M, Luoma A . MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature. 2019; 574(7780):696-701. PMC: 6858572. DOI: 10.1038/s41586-019-1671-8. View

Melief C, van Hall T, Arens R, Ossendorp F, van der Burg S . Therapeutic cancer vaccines. J Clin Invest. 2015; 125(9):3401-12. PMC: 4588240. DOI: 10.1172/JCI80009. View

Simoni Y, Becht E, Fehlings M, Loh C, Koo S, Teng K . Bystander CD8 T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature. 2018; 557(7706):575-579. DOI: 10.1038/s41586-018-0130-2. View

Novy P, Quigley M, Huang X, Yang Y . CD4 T cells are required for CD8 T cell survival during both primary and memory recall responses. J Immunol. 2007; 179(12):8243-51. DOI: 10.4049/jimmunol.179.12.8243. View

Crump M, Neelapu S, Farooq U, Van den Neste E, Kuruvilla J, Westin J . Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017; 130(16):1800-1808. PMC: 5649550. DOI: 10.1182/blood-2017-03-769620. View

Ahrends T, Spanjaard A, Pilzecker B, Babala N, Bovens A, Xiao Y . CD4 T Cell Help Confers a Cytotoxic T Cell Effector Program Including Coinhibitory Receptor Downregulation and Increased Tissue Invasiveness. Immunity. 2017; 47(5):848-861.e5. DOI: 10.1016/j.immuni.2017.10.009. View

Gubin M, Zhang X, Schuster H, Caron E, Ward J, Noguchi T . Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014; 515(7528):577-81. PMC: 4279952. DOI: 10.1038/nature13988. View

Veatch J, Jesernig B, Kargl J, Fitzgibbon M, Lee S, Baik C . Endogenous CD4 T Cells Recognize Neoantigens in Lung Cancer Patients, Including Recurrent Oncogenic and () Driver Mutations. Cancer Immunol Res. 2019; 7(6):910-922. PMC: 6584616. DOI: 10.1158/2326-6066.CIR-18-0402. View

Ossendorp F, Mengede E, Camps M, Filius R, Melief C . Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med. 1998; 187(5):693-702. PMC: 2212165. DOI: 10.1084/jem.187.5.693. View

10.

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky J, Desrichard A . Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189-2199. PMC: 4315319. DOI: 10.1056/NEJMoa1406498. View

11.

Burnet F . The concept of immunological surveillance. Prog Exp Tumor Res. 1970; 13:1-27. DOI: 10.1159/000386035. View

12.

Paradis T, Floyd E, Burkwit J, Cole S, Brunson B, Elliott E . The anti-tumor activity of anti-CTLA-4 is mediated through its induction of IFN gamma. Cancer Immunol Immunother. 2001; 50(3):125-33. PMC: 11036817. DOI: 10.1007/s002620100181. View

13.

Beavis P, Henderson M, Giuffrida L, Davenport A, Petley E, House I . Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4Foxp3 Cell-Mediated Modulation of CD103 Dendritic Cells. Cancer Immunol Res. 2018; 6(9):1069-1081. DOI: 10.1158/2326-6066.CIR-18-0291. View

14.

Cassell D, Forman J . Linked recognition of helper and cytotoxic antigenic determinants for the generation of cytotoxic T lymphocytes. Ann N Y Acad Sci. 1988; 532:51-60. DOI: 10.1111/j.1749-6632.1988.tb36325.x. View

15.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

16.

Tivol E, Borriello F, Schweitzer A, Lynch W, Bluestone J, Sharpe A . Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995; 3(5):541-7. DOI: 10.1016/1074-7613(95)90125-6. View

17.

Bannard O, Cyster J . Germinal centers: programmed for affinity maturation and antibody diversification. Curr Opin Immunol. 2017; 45:21-30. DOI: 10.1016/j.coi.2016.12.004. View

18.

Mohan J, Unanue E . Unconventional recognition of peptides by T cells and the implications for autoimmunity. Nat Rev Immunol. 2012; 12(10):721-8. DOI: 10.1038/nri3294. View

19.

Bennett S, Carbone F, Karamalis F, Flavell R, Miller J, Heath W . Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. 1998; 393(6684):478-80. DOI: 10.1038/30996. View

20.

Turley S, Poirot L, Hattori M, Benoist C, Mathis D . Physiological beta cell death triggers priming of self-reactive T cells by dendritic cells in a type-1 diabetes model. J Exp Med. 2003; 198(10):1527-37. PMC: 2194112. DOI: 10.1084/jem.20030966. View